Press release on ADMIRE study in recurrent cSCC patients
Alpha Tau posted a press release on successful first treatment in its ADMIRE trial using Alpha DaRT for immunocompromised patients with recurrent cSCC.
The procedure took place at Banner MD Anderson Cancer Center in Arizona; the trial targets patients typically excluded from cSCC studies.
The update follows completion of enrollment in the ReSTART pivotal trial for recurrent cSCC.
DRTS•
